Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.
IPO Year: 2020
Exchange: NASDAQ
Website: preludetx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2024 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 6/20/2024 | $3.00 | Equal Weight → Underweight | Barclays |
| 3/13/2024 | $7.00 | Mkt Outperform | JMP Securities |
| 2/20/2024 | $5.00 | Buy → Neutral | H.C. Wainwright |
| 12/19/2023 | $10.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 11/21/2022 | $8.00 → $6.00 | Neutral → Underperform | BofA Securities |
| 9/9/2022 | $19.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/29/2022 | $9.00 | Buy | Jefferies |
| 3/15/2022 | $50.00 → $10.00 | Buy → Neutral | BofA Securities |
| 2/28/2022 | $20.00 → $12.00 | Overweight → Equal-Weight | Barclays |